TIDMBXP
RNS Number : 4825G
Beximco Pharmaceuticals Ltd
16 November 2022
16 November 2022
BEXIMCO PHARMACEUTICALS LIMITED
AGM Notification
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces that the
forty-sixth Annual General Meeting of Shareholders (AGM) of Beximco
Pharma will be held virtually on Thursday 22 December 2022 at 10.30
a.m. to transact the following business:
AGENDA
1. To receive, consider and adopt the Audited Financial
Statements of the Company for the year ended on 30 June 2022
together with reports of the Auditors and the Directors
thereon.
2. To declare 35% Cash Dividend.
3. To elect Directors.
4. To appoint Auditor for the year 2022-2023 and to fix their remuneration.
5. To appoint Corporate Governance Compliance Auditor for the
year 2022-2023 and to fix their remuneration.
By order of the Board
Sd/-
(MOHAMMAD ASAD ULLAH, FCS)
Executive Director & Company
Dated: 15 November 2022 Secretary
NOTES:
(1) Shareholders whose names appear in the Share Register of the
Company or in the Depository Register on the record date (i.e. 21
November 2022) will be entitled to attend the AGM and to receive
the dividend.
(2) A Member entitled to attend and vote at the AGM may appoint
a Proxy to attend and vote in his/her stead. The Proxy Form, duly
stamped, must be deposited at the Registered office of the Company,
not later than 48 hours before the time fixed for the meeting.
(3) Annual Report for the year 2021-22 will be sent through
e-mail address of the Shareholders and will be
available on the Company website at: www.beximcopharma.com .
(4) Shareholders will join the virtual AGM through the link
https://bxpharma.bdvirtualagm.com. Shareholders will be able to
submit their questions/comments and vote electronically one hour
before commencement of the AGM and also during the AGM. For logging
into the system, the Shareholders need to put their 16-digit
Beneficial Owner (BO) ID/Folio Number and other credential as proof
by visiting the said link.
(5) We encourage shareholders to login into the system prior to
the meeting. Please allow ample time to login and establish your
connectivity. For any IT related guidance, shareholders may contact
vide email :
monir@beximco.ne t or mazibur@beximco.net .
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
Jamal Ahmed Choudhury, Director, Accounts & Finance
Tel: +880 2 58611001, Ext.20022
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFLFVFLSLELIF
(END) Dow Jones Newswires
November 16, 2022 02:00 ET (07:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024